Evidence map›Paper›PMID 40926355›Full record

ArticleCancer medicine2025

Real World Evidence of Active Surveillance for Prostate Cancer in Spain; Midterm Results.

J Rubio-Briones, A Borque-Fernando, L M Esteban Escaño, A Wong, A Guijarro Cascales, E Gómez Gómez, J M Gil Fabra, F Sanguedolce, F Gomez-Veiga, P A López González and 41 more

Registry-linked trialAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02865330 (Spanish Urological Association Registry of Patients on Active Surveillance), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02865330 recruitingnot on this map

Spanish Urological Association Registry of Patients on Active Surveillance

Typeobservational_patient_registrySponsorFundación Instituto Valenciano de OncologíaRan2014 to 2034Enrolled946ConditionsProstate CancerArmsRegistry
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

51 authors.

J Rubio-BrionesHospital VITHAS 9 de Octubre, Valencia, Spain.
A Borque-FernandoHospital Miguel Servet, IIS-Aragon, Zaragoza, Spain.ORCID https://orcid.org/0000-0003-0178-4567
L M Esteban EscañoHospital Escuela Universitaria La Almunia, Zaragoza, Spain.
A WongHospital Instituto Valenciano de Oncología, Valencia, Spain.
A Guijarro CascalesHospital Fundación Alcorcón, Madrid, Spain.
E Gómez GómezHospital Reina Sofía, Córdoba, Spain.
J M Gil FabraHospital Miguel Servet, IIS-Aragon, Zaragoza, Spain.
F SanguedolceHospital Fundación Puigvert, Barcelona, Spain.
F Gomez-VeigaHospital Universitario de Salamanca, Salamanca, Spain.
P A López GonzálezHospital Virgen de la Arraixaca, Murcia, Spain.
A Plata BelloHospital Universitario de Canarias, Santa Cruz de Tenerife, Spain.
N Rodríguez GarcíaHospital Son Llatzer, Baleares, Spain.
M Montesino SemperHospital Virgen del Camino, Navarra, Spain.
J F Suárez NovoHospital Universitario Bellvitge, Barcelona, Spain.
R HajianfarHospital Moises Broggi, Barcelona, Spain.
L L Fumadó CiutatHospital del Mar, Barcelona, Spain.
A González AlfaroHospital Móstoles, Madrid, Spain.
J M Duarte OjedaHospital 12 de Octubre, Madrid, Spain.
A Bono AriñoHospital San Jorge, Huesca, Spain.
C Quicios DoradoHospital Fundación Jiménez Díaz, Madrid, Spain.
A Loizaga IriarteHospital Basurto, Vizcaya, Spain.
G García FadriqueHospital Manises, Valencia, Spain.
J M Giménez BachsHospital Universitario Albacete, Albacete, Spain.ORCID https://orcid.org/0000-0003-2549-8813
S García BarrerasHospital Ramón y Cajal, Madrid, Spain.
Y Pallas CostaHospital General Universitario, Valencia, Spain.
A Vilaseca CaboHospital Clínic, Barcelona, Spain.
M Rodrigo AliagaHospital General Universitario, Castellón, Spain.
F Campanario PérezHospital Complejo Asistencial Universitario, Palencia, Spain.
P ServiánHospital Germans Trias i Pujol, Barcelona, Spain.
J M Campá BortolóHospital Universitario de Araba, Alava, Spain.
M Soto DelgadoHospital Puerta del Mar, Cádiz, Spain.
J M Rodríguez de LedesmaHospital CST Terrasa, Barcelona, Spain.
C Sánchez RodríguezHospital Reina Sofía, Murcia, Spain.
V Chantada AbalHospital CHUAC, A Coruña, Spain.
Y E Hernández MartínezHospital Manacor, Baleares, Spain.
B Herrera ImbrodaUGC Intercentros Urología Hospitales Universitarios Virgen de la Victoria y Regional, Málaga, Spain.ORCID https://orcid.org/0000-0002-6235-4897
P DolezalHospital Barbastro, Huesca, Spain.
J Gual FrauHospital Xátiva, Valencia, Spain.
P Medrano LlorenteHospital Clínico Lozano Blesa, Zaragoza, Spain.
J Moreno JiménezComplejo Hospitalario, Jaen, Spain.
J S Serrano UribeHospital Universitario Príncipe de Asturias, Madrid, Spain.
C B Congregado RuizHospital Universitario Vírgen del Rocío, Sevilla, Spain.
A ReyesHospital Calatayud, Ernest Lluch, Zaragoza, Spain.
T Fernández AparicioHospital Morales Messeguer, Murcia, Spain.
J García RodríguezHospital Universitario Central, Asturias, Spain.
M Cuadras SoléHospital Vall d Hebrón, Barcelona, Spain.
A García SeguíHospital General Universitario Elche, Alicante, Spain.
J J Pacheco BruHospital San Juan, Alicante, Spain.
J Mayor de CastroHospital HGU Gregorio Marañón, Madrid, Spain.
A Mira MorenoHospital General de Elda, Alicante, Spain.
J L Molina SuárezHospital Vírgen del Puerto, Extremadura, Spain.

Funding

Government of Aragon (69_23R) and Ministerio de Ciencia, Innovación y Universidades (PID2023-150234NB-I00).
6 · The paper itself

Abstract

PATIENTS AND

methodsIn this multicenter longitudinal study, data from the Spanish Register in AS (AEU-PIEM/2014/0001) were reviewed. The study focused on a cohort of AS patients registered between 2014 and 2019, featuring open inclusion criteria and diverse follow-up strategies.

resultsA total of 3315 AS patients were recruited, with 2881 and 434 categorized into the low and intermediate risk groups based on NCCN grouping at inclusion. The median age was 67 years, and only 11% underwent diagnostic biopsy guided by MRI. The median time between follow-up visits was 6.03 months. Over a median follow-up of 62 months (Q1-3: 43.78-85.58), 37% remained in AS, while 8% transitioned to watchful waiting due to aging or intercurrent disease. Death occurred in 199 (6%) of patients, with 3 due to prostate cancer progression and 196 attributed to other causes. At 2 and 5 years, pathological progression-free survival, metastasis-free survival, and active treatment-free survival were 68% and 51%, 99% and 99%, and 70% and 50%, respectively.

conclusionsMidterm oncological outcomes of AS in Spain align with major international series. We denote underuse of guideline recommendations such as use of MRI or TP Bx for initial PCa characterization. Collaborative efforts are crucial in the search for algorithms, new imaging, or biomarkers to refine indications and transition to active treatments.

trial registrationClinicalTrials.gov identifier: NCT02865330.

Indexed as

Prostatic NeoplasmsWatchful WaitingAgedAged, 80 and overHumansLongitudinal StudiesMagnetic Resonance ImagingMaleMiddle AgedRegistriesSpain

Identifiers

PMID40926355
PMCPMC12420667

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.